Role of Dhataki Pushpa Churna in Heavy Menstrual Bleeding

Efficacy of Dhataki Pushpa Churna in the Disintegration of Pathogenesis of Asrugdara (Heavy Menstrual Bleeding) - A Single arm clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052474

Enrollment

Registered

2023-05-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N921- Excessive and frequent menstruation with irregular cycle

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Duration of menstrual flow >7days Irregular and excessive Menstrual bleeding Reduction in the inter menstrual cycle period Patient with heavy menstrual bleeding since two consecutive cycles atleast

Exclusion criteria

Exclusion criteria: Patients with any co-morbities. Coagulative Disorders Patient with any other organic lesion i.e. uterine fibroid, ovarian cyst, carcinoma etc. IUCD Pregnancy Hb% < 8mg/dl

Design outcomes

Primary

Measure	Time frame
Findings of the study will be beneficial in the clinical management of Asrugdara (Heavy menstrual bleeding) by establishing the efficacy of dhataki pushpa churna .Timepoint: Two Consecutive Cycles	—

Secondary

Measure	Time frame
This study will provide cost effective, safe drug with lesser side effects Timepoint: Two Consecutive Cycles	—

Countries

India

Contacts

Public ContactDr Aditaya Nath Tewari

Ch Brahm Prakash Ayurved Charak Sansthan, Khera Dabar New Delhi

dr.aditaya@gmail.com9711434847

Outcome results